Zacks: Analysts Expect Cambrex Co. (CBM) Will Post Earnings of $0.31 Per Share

Analysts expect Cambrex Co. (NYSE:CBM) to announce $0.31 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Cambrex’s earnings, with the lowest EPS estimate coming in at $0.08 and the highest estimate coming in at $0.53. Cambrex posted earnings of $0.68 per share during the same quarter last year, which would suggest a negative year over year growth rate of 54.4%. The business is expected to issue its next earnings report on Thursday, May 3rd.

On average, analysts expect that Cambrex will report full year earnings of $2.92 per share for the current fiscal year, with EPS estimates ranging from $2.90 to $2.94. For the next fiscal year, analysts anticipate that the business will post earnings of $3.14 per share, with EPS estimates ranging from $3.01 to $3.30. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Cambrex.

How to Become a New Pot Stock Millionaire

Cambrex (NYSE:CBM) last announced its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.17. The business had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 earnings per share.

Several research analysts have recently weighed in on CBM shares. Zacks Investment Research upgraded shares of Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. William Blair started coverage on shares of Cambrex in a research note on Tuesday, January 16th. They issued an “outperform” rating for the company. Finally, Longbow Research downgraded shares of Cambrex from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $60.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Aperio Group LLC boosted its stake in Cambrex by 10.5% during the 4th quarter. Aperio Group LLC now owns 9,759 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 927 shares during the last quarter. Flinton Capital Management LLC boosted its stake in Cambrex by 27.1% during the 4th quarter. Flinton Capital Management LLC now owns 5,100 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 1,088 shares during the last quarter. Palouse Capital Management Inc. boosted its stake in Cambrex by 32.5% during the 4th quarter. Palouse Capital Management Inc. now owns 5,436 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 1,333 shares during the last quarter. American International Group Inc. boosted its stake in Cambrex by 5.8% during the 3rd quarter. American International Group Inc. now owns 25,755 shares of the biotechnology company’s stock valued at $1,417,000 after acquiring an additional 1,417 shares during the last quarter. Finally, Advisor Group Inc. boosted its stake in Cambrex by 52.9% during the 3rd quarter. Advisor Group Inc. now owns 4,100 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 1,419 shares during the last quarter.

Shares of Cambrex stock traded up $0.85 during mid-day trading on Tuesday, hitting $55.95. 631,230 shares of the stock traded hands, compared to its average volume of 251,175. The stock has a market capitalization of $1,837.79, a P/E ratio of 18.22, a PEG ratio of 1.35 and a beta of 2.38. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.

TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3275794/zacks-analysts-expect-cambrex-co-cbm-will-post-earnings-of-0-31-per-share.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Acadia Realty Trust  Cut to Sell at Zacks Investment Research
Acadia Realty Trust Cut to Sell at Zacks Investment Research
Comparing BioFuel Energy  & William Lyon Homes
Comparing BioFuel Energy & William Lyon Homes
Analysts Anticipate LPL Financial  Will Post Earnings of $0.69 Per Share
Analysts Anticipate LPL Financial Will Post Earnings of $0.69 Per Share
Critical Contrast: Virtu Financial  versus The Competition
Critical Contrast: Virtu Financial versus The Competition
Head-To-Head Survey: Sprague Resources  vs. Genesis Energy
Head-To-Head Survey: Sprague Resources vs. Genesis Energy
National Research  vs. Cleveland BioLabs  Critical Survey
National Research vs. Cleveland BioLabs Critical Survey


© 2006-2018 Ticker Report. Google+.